Debunking myths about Irritable Bowel Syndrome
TORONTO, April 18,
2024 /PRNewswire/ -- IBS is a chronic
gastrointestinal disorder with symptoms like abdominal pain,
bloating, constipation, and diarrhea. Misunderstood and
stigmatized, this condition significantly impacts individuals'
quality of life. World IBS Day 2024 includes awareness for patients
with IBS. World IBS Day is now recognized in 17 countries. Events
are listed on the World IBS Day website. Use the hashtag
#WorldIBSDay2024 to raise awareness on April
19th.
Myths confuse patients preventing them from taking the first
step in seeking treatment. Myth #1: IBS is a rare condition. It
affects 10-15% globally and is not a rare condition. While more
women are diagnosed with IBS, IBS is diagnosed in both women and
men. Myth #2: IBS symptoms are the same in everyone. IBS can have
diarrhea, constipation or a mixture of both. Abdominal pain and/or
bloating is common in all forms. Myth #3: The right diet will cure
IBS. The only diet found helpful for people with IBS is the low
FODMAP diet. Is not a permanent diet, rather it helps patients
understand which foods might be bothersome. Myth #4: IBS is all in
your head. IBS involves the gut-brain axis and symptoms in the gut
often overload the brain with signals that they are in
distress.
World IBS Day was established by Jeffrey
Roberts. Jeffrey has been an IBS sufferer for more than
three decades. Jeffrey states that "World IBS Day was created to
show patients that they are not alone living with IBS." He adds,
"We were very grateful to add Ardelyx, Inc as our Lead Partner for
2024 who is leading our Light Up The Sky for IBS campaign. We are
also thankful to include AbbVie and Ironwood as Partners for
2024."
"We're honored to join World IBS Day in their campaign to Light
Up the Sky on April 19th, to bring
visibility to the IBS community and the significant impact the
disease has on patients' quality of life," said Johannah Ruddy, M.Ed, Director, Patient Advocacy
of Ardelyx. "At Ardelyx, we're dedicated to advancing innovation
and improving patient care for individuals living with IBS."
About Jeffrey Roberts:
Jeffrey Roberts, M.Ed, BSc is an
IBS Patient Advocate. He was the creator of the first internet
community for IBS sufferers in 1995. He currently runs the IBS
Patient Support Group, is the co-founder of Tuesday Night IBS and
founded World IBS Day in 2019. He has testified to the US FDA
numerous times sharing what it is like to live with IBS.
About Ardelyx, Inc.:
Ardelyx was founded with a mission to discover, develop and
commercialize innovative, first-in-class medicines that meet
significant unmet medical needs. Ardelyx has two commercial
products approved in the United
States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor) as
well as early-stage pipeline candidates. Ardelyx has agreements for
the development and commercialization of tenapanor outside of the
U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for
hyperphosphatemia in Japan. A New
Drug Application for tenapanor for hyperphosphatemia has been
submitted in China with Fosun
Pharma. Knight Therapeutics commercializes IBSRELA in Canada., please visit ardelyx.com.
Media Contact:
Jeffrey
Roberts, MSEd, BSc
203-424-0660
376394@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/world-ibs-day---april-19th-raising-awareness-for-everyone-with-ibs-302120970.html
SOURCE World IBS Day